Exelixis, Inc.

Genelabs Technologies, Inc.

Smithkline Beecham Corporation

Tanabe Seiyaku Company, Limited

Mitsubishi Tanabe Pharma Corporation

Exelixis Patent Company LLC

X-ceptor Therapeutics, Inc.

Ronald Griffith

Christopher Don Roberts

Richard Martin

Brenton Todd Flatt

Franz Ulrich Schmitz

Nicholas D Smith

Bradley Teegarden

Tie-Lin Wang

Xiao-Hui Gu

Marshall Morningstar

Ila Sircar

Dong-Fang Shi

Paul Furth

Martin Robert Leivers

Ali Dehghani Mohammad Abadi

Raju Mohan

Natalia Dyatkina

Roopa Rai

Marija Prhavc

Alan Thomas Johnson

Jeffrey Dean Kahl

Christopher D Bayne

Janos Botyanszki

Sebastian Johannes Reinhard Liehr

Mikail Hakan Gezginci

Shao-Po Lu

Irina Slobodov

Joshua Michael Gralapp

Compounds, pharmaceutical compositions and methods for modulating the activity of nuclear receptors are provided. In particular, quinazolinones are provided for modulating the activity of farnesoid X receptor (FXR) and/or orphan nuclear receptors.

Quinazolinone modulators of nuclear receptors

Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Compounds, compositions and methods for modulating the activity of nuclear receptors are provided. In particular, heterocyclic compounds are provided for modulating the activity of nuclear receptors, including liver X receptor (LXR) and orphan nuclear receptors. In certain embodiments, the compounds are N-substituted pyridones.

Modulators of LXR

Disclosed are compounds having Formula (I) and the compositions and methods relating to these compounds, for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R, m, R, V, W, T, Z, R, Y, and p are disclosed herein. 

N-(6-membered aromatic ring)-amido anti-viral compounds

Disclosed are compounds having Formula (I) and the compositions and methods thereof for treating or preventing a viral infection mediated at least in part by a virus in the Flaviviridae family of viruses, wherein A, R, m, R, V, W, T, Z, R, Y, and p are disclosed herein. 

N-(5-membered aromatic ring)-amido anti-viral compounds

Disclosed are compounds, compositions and methods for treating Flaviviridae family virus infections.

Bicyclic heteroaryl derivatives

Disclosed are compounds, compositions and methods for treating viral infections caused by a Flaviviridae family virus, such as hepatitis C virus.

Nucleoside compounds for treating viral infections

The present invention relates to a compound of the following formula: or a pharmaceutically acceptable salt thereof. Also disclosed are compositions containing the compound and methods of preparing and using the compounds. The compounds of the invention are useful in treating &#x3b1;&#x3b2;adhesion mediated conditions in a mammal.

[object Object]

Nitrogen-containing heteroaryl derivatives

The present invention relates to a compound of the following formula:or a pharmaceutically acceptable salt thereof. Also disclosed are compositions containing the compound and methods of preparing and using the compounds. The compounds of the invention are useful in treating &#x3b1;&#x3b2;adhesion mediated conditions in a mammal.

Inhibitors of &#x3b1;L&#x3b2;2 mediated cell adhesion

Growing community of inventors

Escondido, CA, United States of America

Ronald Griffith